title: [Conservative treatment of benign prostatic hyperplasia].
abstract: Medical treatment of benign prostatic hyperplasia is reviewed by the author. Experiences with herbal extracts have been known for more than 2 decades. Treating benign prostatic hyperplasia with these extracts is recommended in initial phase. Prostate volume is decreased and mechanical component of dysuria is improved by treating for a long time (months, years) with 5-alpha-reductase finasteride which contains hormone. This drug is indicated when volume of the prostate is over 40 g. Dynamical component of benign prostatic hyperplasia is treated with alpha-receptor blockers which act on the bladder neck. These medicines have effects earlier and are recommended for all patients with benign prostatic hyperplasia independently of prostate volume. These might have some side effects like hypotension. The improving effects of 5-phosphodiesterase inhibitors on BPH have been discovered recently. The same effect has been described of alpha-blockers on sexual activity.
authors.affiliation: Semmelweis Egyetem, Altalános Orvostudományi Kar, Urológiai Klinika, Budapest, Ullôi út 78/b 1082. romimre@urol.sote.hu
authors.forename: Imre
authors.initials: I
authors.lastname: Romics
mesh_terms: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009929:Organ Size / Q000187:drug effects; D008517:Phytotherapy / Q000379:methods*; D010936:Plant Extracts / Q000627:therapeutic use*; D011467:Prostate / Q000187:drug effects / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D014555:Urination Disorders / Q000209:etiology
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D010936:Plant Extracts; D018120:Finasteride